Tiziana Life Sciences (NASDAQ: TLSA) is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis (SPMS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Crohn's disease and more.
